TOP TEN perturbations for 39628_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39628_at
Selected probe(set): 221808_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39628_at (221808_at) across 6674 perturbations tested by GENEVESTIGATOR:

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):-3.9173927
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

dendritic cell study 7 (IL-4 mddc) / dendritic cell study 7 (IL-15 mddc)

Relative Expression (log2-ratio):3.0264473
Number of Samples:3 / 3
Experimental dendritic cell study 7 (IL-4 mddc)
Mature IL-4 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Monocytes were cultured with 800 IU/mL granulocyte macrophage colony-stimulating factor and 20 ng/mL IL-4 in order to generate immature IL-4 DCs. Conventional maturation cocktail, comprising 10 ng/mL tumor necrosis factor-α, 10 ng/mL interleukin-1β, 15 ng/ml interleukin-6 and 1 µg/mL prostaglandin E2 was added for 48 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection.
Control dendritic cell study 7 (IL-15 mddc)
Mature IL-15 dendritic cells differentiated from CD14+ monocytes obtained from healthy donors. Monocytes were seeded in RPMI and supplemented with 2.5 % heat-inactivated human AB serum. Differentiation was induced with 800 IU/mL granulocyte macrophage colony-stimulating factor and 200 ng/mL IL-15 to obtain immature IL-15 DCs. A TLR-activating maturation cocktail, comprising 3 µg/mL R848, 2.5 ng/mL tumor necrosis factor-α, 250 ng/mL interferon-γ and 1 µg/mL prostaglandin E2 was added after 24-48 hours of differentiation for 18-20 hours. CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMC) by Ficoll density gradient centrifugation and purified by positive magnetic cell selection.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (CpG A; RN486)

Relative Expression (log2-ratio):2.7602081
Number of Samples:4 / 4
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (CpG A; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-2.6658173
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) / expO ovary cancer study 1 (endometrioid and clear cell adenocarcinoma; primary)

Relative Expression (log2-ratio):-2.4171057
Number of Samples:3 / 2
Experimental expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)
Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor.
Control expO ovary cancer study 1 (endometrioid and clear cell adenocarcinoma; primary)
Primary tumor tissue samples obtained from the ovary of patients with endometrioid and clear cell adenocarcinoma.

expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary) / expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-2.2410889
Number of Samples:3 / 12
Experimental expO ovary cancer study 1 (malignant mixed Mullerian tumor; primary)
Primary tumor tissue samples obtained from the ovary of patients with malignant mixed Mullerian tumor.
Control expO ovary cancer study 1 (clear cell adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the ovary of patients with clear cell adenocarcinoma (NOS).

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):2.2399416
Number of Samples:4 / 8
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

dendritic cell study 6 (gardiquimod) / dendritic cell study 6 (untreated)

Relative Expression (log2-ratio):2.2199516
Number of Samples:7 / 8
Experimental dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (untreated)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

C. pneumoniae study 1 / uninfected monocyte-derived dendritic cell sample

Relative Expression (log2-ratio):2.1672363
Number of Samples:2 / 2
Experimental C. pneumoniae study 1
Monocyte-derived dendritic cells from healthy donors were infected with Chlamydia pneumoniae at a multiplicity of infection of 5 for 72 h.
Control uninfected monocyte-derived dendritic cell sample
Uninfected monocyte-derived dendritic cells from healthy donors.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-2.1286402
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.